top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.
Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance
Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance
Autore Organization World Health
Pubbl/distr/stampa Geneva, : World Health Organization, 2014
Descrizione fisica 1 online resource (254 p.)
Disciplina 616
Soggetto topico Drug resistance -- Periodicals
Drug resistance in microorganisms
Drug resistance
Anti-infective agents - Classification
Drug resistance in microorganisms - Effect of drugs on
Risk management
Risk
Risk Management
Information Science
Drug Resistance
Microbiological Phenomena
Epidemiologic Measurements
Therapeutic Uses
Probability
Pharmacologic Actions
Pharmacological Phenomena
Public Health
Organization and Administration
Statistics as Topic
Health Services Administration
Environment and Public Health
Chemical Actions and Uses
Physiological Phenomena
Health Care Evaluation Mechanisms
Health Care
Epidemiologic Methods
Drug Therapy
Quality of Health Care
Investigative Techniques
Diagnostic Techniques and Procedures
Health Care Quality, Access, and Evaluation
Anti-Infective Agents
Classification
Risk Assessment
Drug Resistance, Microbial
Biology
Health & Biological Sciences
Microbiology & Immunology
Soggetto genere / forma Publication Formats
Technical Report
ISBN 92-4-069266-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover; Contents; Foreword; Summary; Acknowledgements; Abbreviations; Introduction; SECTION 01 Resistance to antibacterial drugs; 1.1 Background; 1.1.1 Limitations; 1.2 Regional surveillance of antibacterial resistance; 1.2.1 WHO African Region; 1.2.2 WHO Region of the Americas; 1.2.3 WHO Eastern Mediterranean Region; 1.2.4 WHO European Region; 1.2.5 WHO South-East Asia Region; 1.2.6 WHO Western Pacific Region; 1.3 References; SECTION 02 Resistance to antibacterial drugs in selected bacteria of international concern; 2.1 Availability of national resistance data; 2.1.1 Key messages
2.2 Resistance data on specific pathogens2.2.1 Escherichia coli - resistance to third-generation cephalosporins and to fluoroquinolones; 2.2.2 Klebsiella pneumoniae - resistance to third-generation cephalosporins and to carbapenems; 2.2.3 Staphylococcus aureus - resistance to methicillin; 2.2.4 Streptococcus pneumoniae - resistance (non-susceptibility) to penicillin; 2.2.5 Nontyphoidal Salmonella - resistance to fluoroquinolones; 2.2.6 Shigella species - resistance to fluoroquinolones; 2.2.7 Neisseria gonorrhoeae - decreased susceptibility to third-generation cephalosporins; 2.3 References
SECTION 03 The health and economic burden due to antibacterial resistance3.1 Methods; 3.2 Findings; 3.2.1 Health burden; 3.2.2 Economic burden; 3.3 Knowledge gaps; 3.4 Key messages; 3.5 References; SECTION 04 Surveillance of antimicrobial drug resistance in disease-specific programmes; 4.1 Tuberculosis; 4.1.1 Evolution of drug resistance in tuberculosis; 4.1.2 Surveillance of drug-resistant tuberculosis; 4.1.3 Global public health response to drug-resistant tuberculosis; 4.1.4 Notification of MDR-TB cases and enrolment on treatment
4.1.5 Public health implications: treatment outcomes for multidrug-resistant and extensively drug-resistant tuberculosis4.1.6 Key messages; 4.2 Malaria; 4.2.1 Evolution of antimalarial drug resistance; 4.2.2 Surveillance of antimalarial therapeutic efficacy and resistance; 4.2.3 Global public health implications of antimalarial drug resistance; 4.2.4 Key messages; 4.3 HIV; 4.3.1 Surveillance of anti-HIV drug resistance; 4.3.2 Global public health implications of anti-HIV drug resistance; 4.3.3 Key messages; 4.4 Influenza; 4.4.1 Evolution of resistance in influenza viruses
4.4.2 Anti-influenza drug resistance4.4.3 Surveillance of anti-influenza drug resistance; 4.4.4 Public health implications of anti-influenza drug resistance; 4.4.5 Key messages; 4.5 References; SECTION 05 Surveillance of antimicrobial resistance in other areas; 5.1 Antibacterial resistance in food-producing animals and the food chain; 5.1.1 Ongoing surveillance of antimicrobial resistance in food-producing animals and food; 5.1.2 Integrated surveillance of antimicrobial resistance in foodborne bacteria; 5.1.3 Antimicrobials of particular importance in human and veterinary medicine
5.1.4 Implications for human health from zoonotic transmission of resistant bacteria and genetic material
Record Nr. UNINA-9910825162403321
Organization World Health  
Geneva, : World Health Organization, 2014
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials
Autore Kazmierski Wieslaw M
Pubbl/distr/stampa Hoboken, : Wiley, 2011
Descrizione fisica 1 online resource (470 p.)
Disciplina 615/.7924
Soggetto topico Antiviral Agents -- therapeutic use
Antiviral agents
Clinical Trials as Topic
Drug Discovery
Drug Evaluation
Epidemiologic Studies
Chemistry, Pharmaceutical
Evaluation Studies as Topic
Investigative Techniques
Anti-Infective Agents
Epidemiologic Methods
Pharmacology
Therapeutic Uses
Health Care Evaluation Mechanisms
Chemistry
Biological Science Disciplines
Natural Science Disciplines
Quality of Health Care
Public Health
Pharmacologic Actions
Environment and Public Health
Health Care Quality, Access, and Evaluation
Chemical Actions and Uses
Health Care
Antiviral Agents
Health & Biological Sciences
Pharmacy, Therapeutics, & Pharmacology
ISBN 1-283-20363-4
9786613203632
0-470-92935-9
0-470-92934-0
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients
7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir
14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection
21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir
29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate
Record Nr. UNINA-9910139613803321
Kazmierski Wieslaw M  
Hoboken, : Wiley, 2011
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials
Autore Kazmierski Wieslaw M
Pubbl/distr/stampa Hoboken, : Wiley, 2011
Descrizione fisica 1 online resource (470 p.)
Disciplina 615/.7924
Soggetto topico Antiviral Agents -- therapeutic use
Antiviral agents
Clinical Trials as Topic
Drug Discovery
Drug Evaluation
Epidemiologic Studies
Chemistry, Pharmaceutical
Evaluation Studies as Topic
Investigative Techniques
Anti-Infective Agents
Epidemiologic Methods
Pharmacology
Therapeutic Uses
Health Care Evaluation Mechanisms
Chemistry
Biological Science Disciplines
Natural Science Disciplines
Quality of Health Care
Public Health
Pharmacologic Actions
Environment and Public Health
Health Care Quality, Access, and Evaluation
Chemical Actions and Uses
Health Care
Antiviral Agents
Health & Biological Sciences
Pharmacy, Therapeutics, & Pharmacology
ISBN 1-283-20363-4
9786613203632
0-470-92935-9
0-470-92934-0
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients
7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir
14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection
21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir
29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate
Record Nr. UNINA-9910808713803321
Kazmierski Wieslaw M  
Hoboken, : Wiley, 2011
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Applications of Toxicogenomics in Safety Evaluation and Risk Assessment [[electronic resource]]
Applications of Toxicogenomics in Safety Evaluation and Risk Assessment [[electronic resource]]
Autore Boverhof Darrell R
Pubbl/distr/stampa Hoboken, : Wiley, 2011
Descrizione fisica 1 online resource (402 p.)
Disciplina 616.042
616/.042
Altri autori (Persone) GollapudiB. Bhaskar
Soggetto topico Genetic toxicology
Health risk assessment
Risk Assessment
Toxicity testing
Toxicogenetics
Toxicology
Pharmacogenetics
Risk
Risk Management
Epidemiologic Measurements
Organization and Administration
Pharmacology
Probability
Genetics
Public Health
Health Occupations
Statistics as Topic
Biological Science Disciplines
Biology
Health Services Administration
Environment and Public Health
Natural Science Disciplines
Health Care
Health Care Evaluation Mechanisms
Epidemiologic Methods
Quality of Health Care
Investigative Techniques
Health Care Quality, Access, and Evaluation
Health & Biological Sciences
Toxicology & Public Health
Soggetto genere / forma Electronic books.
ISBN 1-283-23966-3
9786613239662
1-118-00104-4
1-118-00103-6
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Contents; Preface; Contributors; 1 Toxicology, ""Omics"" Technologies, and Toxicogenomics: A Primer; 2 Introduction to Human Health Risk Assessment; 3 Practical Considerations for the Application of Toxicogenomics to Risk Assessment: Early Experience, Current Drivers, and a Path Forward; 4 Approaches and Practical Considerations for the Analysis of Toxicogenomics Data; 5 Genomics in Identifying Mutagenic Mode of Action in Carcinogenesis; 6 Application of Genomics for Predicting and Understanding the Mode of Action for Nongenotoxic Carcinogens; 7 Genomics in Characterizing Endocrine Toxicity
8 Studying Organ-Specific Toxicity Using Gene-Expression Profiling9 Toxicogenomic Studies in Human Populations; 10 Toxicogenomics Applied to Ecological Risk Assessment; 11 Analysis of Transcriptomic Dose-Response Data for Toxicology and Risk Assessment; 12 Toxicogenomics as a Tool for Validating Animal to Human Extrapolations in Chemical Risk Assessment: Concepts, Applications, and Challenges; 13 Toxicogenomics and Animal Alternatives; 14 Toxicogenomics and the Regulatory Framework; 15 Standardization of Gene-Expression Information for the Safety Evaluation: Activities in Japan
16 Applying Transcriptional Profiling in Drug Safety Evaluation17 Reframing the Risk Assessment Paradigm: Toward a Systems Biology Approach; Index
Record Nr. UNINA-9910139607903321
Boverhof Darrell R  
Hoboken, : Wiley, 2011
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Applications of Toxicogenomics in Safety Evaluation and Risk Assessment [[electronic resource]]
Applications of Toxicogenomics in Safety Evaluation and Risk Assessment [[electronic resource]]
Autore Boverhof Darrell R
Edizione [First edition.]
Pubbl/distr/stampa Hoboken : , : Wiley, , 2011
Descrizione fisica 1 online resource (402 pages)
Disciplina 616.042
616/.042
Altri autori (Persone) GollapudiB. Bhaskar
Soggetto topico Genetic toxicology
Health risk assessment
Risk Assessment
Toxicity testing
Toxicogenetics
Toxicology
Pharmacogenetics
Risk
Risk Management
Epidemiologic Measurements
Organization and Administration
Pharmacology
Probability
Genetics
Public Health
Health Occupations
Statistics as Topic
Biological Science Disciplines
Biology
Health Services Administration
Environment and Public Health
Natural Science Disciplines
Health Care
Health Care Evaluation Mechanisms
Epidemiologic Methods
Quality of Health Care
Investigative Techniques
Health Care Quality, Access, and Evaluation
Health & Biological Sciences
Toxicology & Public Health
ISBN 1-283-23966-3
9786613239662
1-118-00104-4
1-118-00103-6
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Contents; Preface; Contributors; 1 Toxicology, ""Omics"" Technologies, and Toxicogenomics: A Primer; 2 Introduction to Human Health Risk Assessment; 3 Practical Considerations for the Application of Toxicogenomics to Risk Assessment: Early Experience, Current Drivers, and a Path Forward; 4 Approaches and Practical Considerations for the Analysis of Toxicogenomics Data; 5 Genomics in Identifying Mutagenic Mode of Action in Carcinogenesis; 6 Application of Genomics for Predicting and Understanding the Mode of Action for Nongenotoxic Carcinogens; 7 Genomics in Characterizing Endocrine Toxicity
8 Studying Organ-Specific Toxicity Using Gene-Expression Profiling9 Toxicogenomic Studies in Human Populations; 10 Toxicogenomics Applied to Ecological Risk Assessment; 11 Analysis of Transcriptomic Dose-Response Data for Toxicology and Risk Assessment; 12 Toxicogenomics as a Tool for Validating Animal to Human Extrapolations in Chemical Risk Assessment: Concepts, Applications, and Challenges; 13 Toxicogenomics and Animal Alternatives; 14 Toxicogenomics and the Regulatory Framework; 15 Standardization of Gene-Expression Information for the Safety Evaluation: Activities in Japan
16 Applying Transcriptional Profiling in Drug Safety Evaluation17 Reframing the Risk Assessment Paradigm: Toward a Systems Biology Approach; Index
Record Nr. UNINA-9910824275603321
Boverhof Darrell R  
Hoboken : , : Wiley, , 2011
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Applied Health Economics - Second Edition [[electronic resource]]
Applied Health Economics - Second Edition [[electronic resource]]
Autore Jones Andrew M
Edizione [2nd ed.]
Pubbl/distr/stampa Hoboken, : Taylor and Francis, 2013
Descrizione fisica 1 online resource (417 p.)
Disciplina 338.473621
Altri autori (Persone) RiceNigel
Bago d'UvaTeresa
BaliaSilvia
Collana Routledge Advanced Texts in Economics and Finance
Soggetto topico Economics, Medical
Health Care Costs
Statistics as Topic
Economics
Delivery of Health Care
Health Care Evaluation Mechanisms
Costs and Cost Analysis
Epidemiologic Methods
Mathematics
Investigative Techniques
Health Care Quality, Access, and Evaluation
Quality of Health Care
Natural Science Disciplines
Public Health
Health Care Economics and Organizations
Health Care
Environment and Public Health
Health & Biological Sciences
Medical Economics
Soggetto genere / forma Electronic books.
ISBN 0-203-10241-X
1-136-23982-0
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover; Title; Copyright; Contents; List of illustrations; Preface; Acknowledgements; Introduction; PART I Describing and summarising data; 1 Data and survey design; 1.1 The Health and Lifestyle Survey; 1.2 The British Household Panel Survey; 1.3 The European Community Household Panel; 1.4 The US Medical Expenditure Panel Survey; 1.5 Survey of Health, Ageing and Retirement in Europe; 1.6 Overview; 2 Describing the dynamics of health; 2.1 Introduction; 2.2 Graphical analysis; 2.3 Tabulating the data; 2.4 Overview; 3 Describing health care costs; 3.1 Introduction; 3.2 Data description
3.3 Modelling health care cost data3.4 Linear regression models; 3.5 Overview; PART II Categorical data; 4 Reporting heterogeneity in health; 4.1 Introduction; 4.2 Data; 4.3 Standard analysis; 4.4 Using vignettes; 4.5 Overview; Appendix; 5 Health and lifestyles; 5.1 Introduction; 5.2 HALS data and sample; 5.3 Descriptive analysis; 5.4 Estimation strategy and results; 5.5 Overview; PART III Duration data; 6 Smoking and mortality; 6.1 Introduction; 6.2 Basic concepts of duration analysis; 6.3 The HALS data; 6.4 Duration data in HALS; 6.5 Descriptive statistics; 6.6 Duration models; 6.7 Overview
7 Health and retirement7.1 Introduction; 7.2 Preparing and summarising the data; 7.3 Dealing with self-reported health; 7.4 Empirical approach to duration modelling; 7.5 Stock sampling and discrete-time hazard analysis; 7.6 Overview; PART IV Panel data; 8 Health and wages; 8.1 Introduction; 8.2 BHPS sample and variables; 8.3 Empirical model and estimation; 8.4 Overview; Appendix; 9 Modelling the dynamics of health; 9.1 Introduction; 9.2 Static models; 9.3 Dynamic models; 9.4 Overview; 10 Non-response and attrition bias; 10.1 Introduction; 10.2 Testing for non-response bias; 10.3 Estimation
10.4 OverviewAppendix; PART V Health care data; 11 Models for count data; 11.1 Introduction; 11.2 The Poisson model; 11.3 The negative binomial model; 11.4 Zero-inflated models; 11.5 Hurdle models; 11.6 Finite mixture/latent class models; 11.7 Latent class models for panel data; 11.8 Overview; Appendix; 12 Modelling health care costs; 12.1 Introduction; 12.2 Exponential conditional mean models; 12.3 Generalised linear models; 12.4 Finite mixture models; 12.5 Comparing model performance; 12.6 Overview; Bibliography; Index
Record Nr. UNINA-9910462932703321
Jones Andrew M  
Hoboken, : Taylor and Francis, 2013
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Applied Health Economics - Second Edition [[electronic resource]]
Applied Health Economics - Second Edition [[electronic resource]]
Autore Jones Andrew M
Edizione [Second edition.]
Pubbl/distr/stampa Hoboken, : Taylor and Francis, 2013
Descrizione fisica 1 online resource (417 pages)
Disciplina 338.473621
Altri autori (Persone) RiceNigel
Bago d'UvaTeresa <1976->
BaliaSilvia
Collana Routledge Advanced Texts in Economics and Finance
Soggetto topico Economics, Medical
Health Care Costs
Statistics as Topic
Economics
Delivery of Health Care
Health Care Evaluation Mechanisms
Costs and Cost Analysis
Epidemiologic Methods
Mathematics
Investigative Techniques
Health Care Quality, Access, and Evaluation
Quality of Health Care
Natural Science Disciplines
Public Health
Health Care Economics and Organizations
Health Care
Environment and Public Health
Health & Biological Sciences
Medical Economics
ISBN 0-203-10241-X
1-136-23982-0
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover; Title; Copyright; Contents; List of illustrations; Preface; Acknowledgements; Introduction; PART I Describing and summarising data; 1 Data and survey design; 1.1 The Health and Lifestyle Survey; 1.2 The British Household Panel Survey; 1.3 The European Community Household Panel; 1.4 The US Medical Expenditure Panel Survey; 1.5 Survey of Health, Ageing and Retirement in Europe; 1.6 Overview; 2 Describing the dynamics of health; 2.1 Introduction; 2.2 Graphical analysis; 2.3 Tabulating the data; 2.4 Overview; 3 Describing health care costs; 3.1 Introduction; 3.2 Data description
3.3 Modelling health care cost data3.4 Linear regression models; 3.5 Overview; PART II Categorical data; 4 Reporting heterogeneity in health; 4.1 Introduction; 4.2 Data; 4.3 Standard analysis; 4.4 Using vignettes; 4.5 Overview; Appendix; 5 Health and lifestyles; 5.1 Introduction; 5.2 HALS data and sample; 5.3 Descriptive analysis; 5.4 Estimation strategy and results; 5.5 Overview; PART III Duration data; 6 Smoking and mortality; 6.1 Introduction; 6.2 Basic concepts of duration analysis; 6.3 The HALS data; 6.4 Duration data in HALS; 6.5 Descriptive statistics; 6.6 Duration models; 6.7 Overview
7 Health and retirement7.1 Introduction; 7.2 Preparing and summarising the data; 7.3 Dealing with self-reported health; 7.4 Empirical approach to duration modelling; 7.5 Stock sampling and discrete-time hazard analysis; 7.6 Overview; PART IV Panel data; 8 Health and wages; 8.1 Introduction; 8.2 BHPS sample and variables; 8.3 Empirical model and estimation; 8.4 Overview; Appendix; 9 Modelling the dynamics of health; 9.1 Introduction; 9.2 Static models; 9.3 Dynamic models; 9.4 Overview; 10 Non-response and attrition bias; 10.1 Introduction; 10.2 Testing for non-response bias; 10.3 Estimation
10.4 OverviewAppendix; PART V Health care data; 11 Models for count data; 11.1 Introduction; 11.2 The Poisson model; 11.3 The negative binomial model; 11.4 Zero-inflated models; 11.5 Hurdle models; 11.6 Finite mixture/latent class models; 11.7 Latent class models for panel data; 11.8 Overview; Appendix; 12 Modelling health care costs; 12.1 Introduction; 12.2 Exponential conditional mean models; 12.3 Generalised linear models; 12.4 Finite mixture models; 12.5 Comparing model performance; 12.6 Overview; Bibliography; Index
Record Nr. UNINA-9910786719003321
Jones Andrew M  
Hoboken, : Taylor and Francis, 2013
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Applied Health Economics - Second Edition [[electronic resource]]
Applied Health Economics - Second Edition [[electronic resource]]
Autore Jones Andrew M
Edizione [Second edition.]
Pubbl/distr/stampa Hoboken, : Taylor and Francis, 2013
Descrizione fisica 1 online resource (417 pages)
Disciplina 338.473621
Altri autori (Persone) RiceNigel
Bago d'UvaTeresa <1976->
BaliaSilvia
Collana Routledge Advanced Texts in Economics and Finance
Soggetto topico Economics, Medical
Health Care Costs
Statistics as Topic
Economics
Delivery of Health Care
Health Care Evaluation Mechanisms
Costs and Cost Analysis
Epidemiologic Methods
Mathematics
Investigative Techniques
Health Care Quality, Access, and Evaluation
Quality of Health Care
Natural Science Disciplines
Public Health
Health Care Economics and Organizations
Health Care
Environment and Public Health
Health & Biological Sciences
Medical Economics
ISBN 0-203-10241-X
1-136-23982-0
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover; Title; Copyright; Contents; List of illustrations; Preface; Acknowledgements; Introduction; PART I Describing and summarising data; 1 Data and survey design; 1.1 The Health and Lifestyle Survey; 1.2 The British Household Panel Survey; 1.3 The European Community Household Panel; 1.4 The US Medical Expenditure Panel Survey; 1.5 Survey of Health, Ageing and Retirement in Europe; 1.6 Overview; 2 Describing the dynamics of health; 2.1 Introduction; 2.2 Graphical analysis; 2.3 Tabulating the data; 2.4 Overview; 3 Describing health care costs; 3.1 Introduction; 3.2 Data description
3.3 Modelling health care cost data3.4 Linear regression models; 3.5 Overview; PART II Categorical data; 4 Reporting heterogeneity in health; 4.1 Introduction; 4.2 Data; 4.3 Standard analysis; 4.4 Using vignettes; 4.5 Overview; Appendix; 5 Health and lifestyles; 5.1 Introduction; 5.2 HALS data and sample; 5.3 Descriptive analysis; 5.4 Estimation strategy and results; 5.5 Overview; PART III Duration data; 6 Smoking and mortality; 6.1 Introduction; 6.2 Basic concepts of duration analysis; 6.3 The HALS data; 6.4 Duration data in HALS; 6.5 Descriptive statistics; 6.6 Duration models; 6.7 Overview
7 Health and retirement7.1 Introduction; 7.2 Preparing and summarising the data; 7.3 Dealing with self-reported health; 7.4 Empirical approach to duration modelling; 7.5 Stock sampling and discrete-time hazard analysis; 7.6 Overview; PART IV Panel data; 8 Health and wages; 8.1 Introduction; 8.2 BHPS sample and variables; 8.3 Empirical model and estimation; 8.4 Overview; Appendix; 9 Modelling the dynamics of health; 9.1 Introduction; 9.2 Static models; 9.3 Dynamic models; 9.4 Overview; 10 Non-response and attrition bias; 10.1 Introduction; 10.2 Testing for non-response bias; 10.3 Estimation
10.4 OverviewAppendix; PART V Health care data; 11 Models for count data; 11.1 Introduction; 11.2 The Poisson model; 11.3 The negative binomial model; 11.4 Zero-inflated models; 11.5 Hurdle models; 11.6 Finite mixture/latent class models; 11.7 Latent class models for panel data; 11.8 Overview; Appendix; 12 Modelling health care costs; 12.1 Introduction; 12.2 Exponential conditional mean models; 12.3 Generalised linear models; 12.4 Finite mixture models; 12.5 Comparing model performance; 12.6 Overview; Bibliography; Index
Record Nr. UNINA-9910824051303321
Jones Andrew M  
Hoboken, : Taylor and Francis, 2013
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Assessment and Reclamation of Contaminated Land [[electronic resource]]
Assessment and Reclamation of Contaminated Land [[electronic resource]]
Autore Harrison Roy M. <1948->
Edizione [1st ed.]
Pubbl/distr/stampa Cambridge, : Royal Society of Chemistry, 2001
Descrizione fisica 1 online resource (180 p.)
Disciplina 628.55
Altri autori (Persone) HesterR. E
PollardS.imon
Collana Issues in Environmental Science and Technology
Soggetto topico Reclamation of land -- Great Britain
Soil pollution -- Great Britain
Soil pollution -- Law and legislation -- Great Britain
Soil remediation -- Great Britain
Soil pollution - Law and legislation - Great Britain
Soil pollution - Great Britain
Soil remediation - Great Britain
Reclamation of land - Great Britain
Risk Management
Risk
Epidemiologic Measurements
Environmental Pollutants
Public Health
Probability
Toxic Actions
Organization and Administration
Statistics as Topic
Chemical Actions and Uses
Environment and Public Health
Health Services Administration
Health Care
Epidemiologic Methods
Health Care Evaluation Mechanisms
Investigative Techniques
Quality of Health Care
Health Care Quality, Access, and Evaluation
Soil Pollutants
Risk Assessment
Civil & Environmental Engineering
Engineering & Applied Sciences
Environmental Engineering
ISBN 1-84755-017-7
1-59124-419-6
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto CONTENTS; The Extent of Contaminated Land Problems and the Scientific Response; 1 The Origins of Contaminated Land Problems; 2 The Extent of the Challenge; 3 Developments in the Science Base; 4 Conclusions; 5 Acknowledgements; The New UK Contaminated Land Regime; 1 Introduction; 2 The Context forPart IIA; 3 The Part IIA System; 4 Dealing with 'Risk'; 5 Making People Pay; 6 Part IIA as a 'Regulatory System'; 7 The State of Play; 8 What Next?; Identifying and Dealing with Contaminated Land; 1 Introduction; 2 Site Assessment; 3 Risk Management; 4 Measurement of Site Contamination; 5 Conclusions
Contaminated Land and the Link with Health1 Introduction; 2 Exposure; 3 Health Studies; 4 Case Studies; 5 Conclusion; Human Health Risk Assessment: Guideline Values and Magic Numbers; 1 Land Contamination Policy; 2 Risk Assessment; 3 What Is a Guideline Value?; 4 The Use of Guideline Values; 5 The CLEA Model; 6 The SNIFFER Framework; 7 Conclusions; 8 Acknowledgements; Ecological Risk Assessment under the New Contaminated Land Regime; 1 Background and Legal Context; 2 Harm to Ecological Receptors; 3 General Approach to the Assessment of Land Under the NewRegime
4 Assessing Whether Significant Harm to Ecological Receptors Is Occurring5 Assessing the Possibility of Significant Harm Occurring; 6 The Environment Agency's Suggested Approach; 7 Guideline Values; 8 Comments and Discussion; Remediation Methods for Contaminated Sites; 1 Introduction; 2 Summary of Remediation Approaches; 3 Selected Innovative Approaches; 4 Summary and Conclusions; Legal Liabilities and Insurance Aspects of Contaminated Land; 1 Introduction; 2 Contaminated Land; 3 Statutory Provisions in the UK; 4 Sale of Land/Businesses; 5 Principles of Insurance
6 History of Environmental Insurance7 Land Owners and Environmental Liabilities; 8 Pollution Liabilities for Contaminated Land Sites; 9 Current Manufacturing Activities; 10 Environmental Insurance; 11 Environmental Consultants; 12 Collateral Warranties; 13 Contractors; 14 An Example; 15 Conclusion; Subject Index
Record Nr. UNINA-9910142515703321
Harrison Roy M. <1948->  
Cambridge, : Royal Society of Chemistry, 2001
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program [[electronic resource]]
Assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program [[electronic resource]]
Autore Staff Institute of Medicine
Pubbl/distr/stampa Washington, : National Academies Press, 2002
Descrizione fisica 1 online resource (179 p.)
Disciplina 615
Soggetto topico Anthrax -- Vaccination
Public health
Anthrax - Vaccination - Research - United States
Bacterial Vaccines
Evaluation Studies as Topic
Health Care Evaluation Mechanisms
Quality of Health Care
Bacillaceae Infections
Investigative Techniques
Vaccines
Health Services Administration
Gram-Positive Bacterial Infections
Bacterial Infections
Health Care Quality, Access, and Evaluation
Health Care
Analytical, Diagnostic and Therapeutic Techniques and Equipment
Biological Products
Complex Mixtures
Bacterial Infections and Mycoses
Chemicals and Drugs
Diseases
Program Evaluation
Drug Evaluation
Anthrax
Anthrax Vaccines
Public Health
Health & Biological Sciences
Communicable Diseases
Soggetto genere / forma Electronic books.
ISBN 0-309-50374-4
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto ""Front Matter""; ""Preface""; ""Reviewers""; ""Contents""; ""Figures, Tables, and Boxes""; ""Abbreviations and Acronyms""; ""Executive Summary""; ""1 Introduction""; ""2 Background""; ""3 The CDC Anthrax Vaccine Research Plan""; ""4 Proposed Studies on the Efficacy of the Anthrax Vaccine""; ""5 Proposed Studies on the Safety of the Anthrax Vaccine""; ""6 Proposed Studies on the Acceptability of the Anthrax Vaccine""; ""7 Summary Assessment of the CDC Anthrax Vaccine Research Plan""; ""Appendix A Biographical Sketches""; ""Appendix B Information-Gathering Meeting Agendas""
""Appendix C Anthrax Vaccine Safety & Efficacy Research Plan""""Appendix D Food and Drug Administration Final Rule: New Drug and Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible""; ""Appendix E Department of Defense Memorandum: Reintroduction of the Anthrax Vaccine Immunization Program""; ""Appendix F Institute of Medicine: CDC Anthrax Vaccine Safety & Efficacy Research Program. Interim Report Findings and Recommendations1""
""Appendix G Institute of Medicine: The Anthrax Vaccine: Is It Safe? Does It Work? Findings and Recommendations1""
Record Nr. UNINA-9910455868803321
Staff Institute of Medicine  
Washington, : National Academies Press, 2002
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui